論文 - 詳細
| RRC ID | 17648 |
|---|---|
| 著者 | Saito Y, Nakahata S, Yamakawa N, Kaneda K, Ichihara E, Suekane A, Morishita K. |
| タイトル | CD52 as a molecular target for immunotherapy to treat acute myeloid leukemia with high EVI1 expression. |
| ジャーナル | Leukemia |
| Abstract |
Ecotropic viral integration site 1 (EVI1) is an oncogenic transcription factor in human acute myeloid leukemia (AML) with chromosomal alterations at 3q26. Because a high expression of EVI1 protein in AML cells predicts resistance to chemotherapy with a poor outcome, we have searched for molecular targets that will treat these patients with AML. In this study, we determined that CD52, which is mainly expressed on lymphocytes, is highly expressed in most cases of AML with a high EVI1 expression (EVI1(High)). CAMPATH-1H, a humanized monoclonal antibody against CD52, has been used to prevent graft-versus-host disease and treat CD52-positive lymphoproliferative disorders. Here, we investigated the antitumor effect of CAMPATH-1H on EVI1(High) AML cells. CAMPATH-1H significantly inhibited cell growth and induced apoptosis in CD52-positive EVI1(High) leukemia cells. Furthermore, CAMPATH-1H induced complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity against CD52-positive EVI1(High) leukemia cells. After an intravenous injection of CAMPATH-1H into NOD/Shi-scid/IL-2Rγ;null mice with subcutaneous engraftment of EVI1(High) leukemia cells, tumor growth rates were significantly reduced, and the mice survived longer than those in the phosphate-buffered saline-injected control group. Thus, CAMPATH-1H is a potential therapeutic antibody for the treatment of patients with EVI1(High) leukemia. |
| 巻・号 | 25(6) |
| ページ | 921-31 |
| 公開日 | 2011-6-1 |
| DOI | 10.1038/leu.2011.36 |
| PII | leu201136 |
| PMID | 21394097 |
| MeSH | Animals Antigens, CD / analysis* Antigens, Neoplasm / analysis* CD52 Antigen DNA-Binding Proteins / analysis* Glycoproteins / analysis* Humans Immunotherapy / methods* Leukemia, Myeloid, Acute / drug therapy* Leukemia, Myeloid, Acute / immunology MDS1 and EVI1 Complex Locus Protein Mice Molecular Targeted Therapy / methods* Proto-Oncogenes Transcription Factors / analysis* Tumor Cells, Cultured Xenograft Model Antitumor Assays |
| IF | 8.665 |
| 引用数 | 31 |
| WOS 分野 | ONCOLOGY HEMATOLOGY |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | Patent(IFI CLAIMS) |
| 各媒体での言及数の合計 | 7 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | HNT-34(RCB1296) U-937 DE-4(RCB0435) K562(RCB0027) KG-1(RCB1166) HL60(RCB0041) THP-1(RCB1189) |